Shree Ganesh Remedies valuation

Share price at each year-end
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024
Price multiples — at each FY-end close
47.54×———
5.18×———
7.73×———
35.58×———
Enterprise multiples
7.78×———
24.27×———
34.62×———
Yield
2.1%———
2.8%———
Reference — adjusted share basis
₹658.00———
₹13.84₹13.84₹17.99₹21.90
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SGRL₹658.00

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOCMcap ₹845 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
Price Multiples — at each FY-end close
P/E———47.54
P/B———5.18
P/Sales———7.73
Price to Free Cash Flow———35.58
Enterprise Multiples
EV/Sales———7.78
EV/EBITDA———24.27
EV/EBIT———34.62
Yield
Earnings Yield %———2.10
FCF Yield %———2.81
Reference — adjusted share basis
Price (FY-end close, adj.)———658.00
EPS (adj.)21.9017.9913.8413.84
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.